SZLSF (StageZero Life Sciences) Tariff Resilience Score: 0/10 (As of Jul. 01, 2026)


SZLSF StageZero Life Sciences Ltd SZLSF
10 GF Score
Price $0.01
View Full Analysis

What is StageZero Life Sciences Tariff Resilience Score?

StageZero Life Sciences has the Tariff Resilience Score of 0, which implies that the company might have .

StageZero Life Sciences has StageZero's operations are primarily service-based with limited physical goods trade, reducing tariff exposure. Its global supply chain is minimal, and it can leverage digital platforms. However, any tariffs on medical equipment could impact costs indirectly.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes StageZero Life Sciences might have .

StageZero Life Sciences  (OTCPK:SZLSF) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

StageZero Life Sciences Tariff Resilience Score Related Terms

SZLSF
10GF Score
StageZero Life Sciences Ltd SZLSF
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

StageZero Life Sciences Business Description

Address 70 East Beaver Creek Road, Unit 30, Richmond Hill, ON, CAN, L4B 3B2
StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.
10GF Score

Get the complete analysis for SZLSF

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.01
Price